Condition: Nasopharyngeal Carcinoma · Sponsor: Jiangxi Provincial Cancer Hospital
The purpose of this study is to explore the efficacy and safety of a combination regimen of Anti-PD1 monoclonal antibody, nimotuzumab, and capecitabin in treating recurrent or metastatic nasopharyngeal carcinoma patients who have failed first-line platinum-based chemotherapy.
This description comes directly from the study's public registry record.
Jingao Li, MD · 86079188300252 · lijingao@hotmail.com
Xiaochang Gong, MD · 86079188300252 · gxcanddw@163.com
Always discuss trial participation with your own doctor first.
| Department of Nasopharyngeal Carcinoma, Jiangxi Cancer Hospital | Nanchang, Jiangxi, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06259721